#### MEDICINES CO/DE

Form 4

September 02, 2015

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue.

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

See Instruction

1. Name and Address of Reporting Person * SBLENDORIO GLENN			2. Issuer Name <b>and</b> Ticker or Trading Symbol MEDICINES CO /DE [MDCO]	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction	(Check an applicable)		
8 SYLVAN WAY			(Month/Day/Year) 08/31/2015	_X Director 10% Owner X Officer (give title Other (specify below) President & CFO		
(Street)			4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
			Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting		
PARSIPPANY, NJ 07054				Person		

(City)	(State)	(Zip) Tal	ble I - Non-	-Derivative	Securi	ities Acquire	ed, Disposed of, o	or Beneficially	<b>Owned</b>
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securitie orDisposed o (Instr. 3, 4	of (D)	uired (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/31/2015		A A	266 (1)	A	\$ 24.74	99,805	D	
Common Stock	08/31/2015		M	40,000	A	\$ 28.6	139,805	D	
Common Stock	08/31/2015		M	24,495	A	\$ 19.36	164,300	D	
Common Stock	08/31/2015		M	50,000	A	\$ 17.45	214,300	D	
Common Stock	08/31/2015		S	114,495 (2)	D	\$ 39.7537 (3)	99,805	D	

#### Edgar Filing: MEDICINES CO /DE - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	ive Expiration Date les (Month/Day/Year) ed (A) osed of		7. Title and Amount Underlying Securition (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Sha
Stock Option (right-to-buy)	\$ 28.6	08/31/2015		M	40,000	<u>(4)</u>	02/16/2017	Common Stock	40,0
Stock Option (right-to-buy)	\$ 19.36	08/31/2015		M	24,495	<u>(5)</u>	02/15/2018	Common Stock	24,4
Stock Option (right-to-buy)	\$ 17.45	08/31/2015		M	50,000	<u>(6)</u>	02/18/2021	Common Stock	50,0

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
r	Director	10% Owner	Officer	Other			
SBLENDORIO GLENN 8 SYLVAN WAY PARSIPPANY, NJ 07054	X		President & CFO				

## **Signatures**

/s/ Stephen M. Rodin, Attorney-in-Fact for Glenn P.
Sblendorio
09/02/2015

Date

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning March (1) 1, 2015 and ending August 31, 2015. In accordance with the terms of the ESPP, these shares were purchased based on 85% of the fair market value closing price of the issuer's common stock on March 2, 2015.
- (2) Sales were effected pursuant to a Rule 10b5-1 program adopted by the reporting person.

Reporting Owners 2

### Edgar Filing: MEDICINES CO /DE - Form 4

- Represents the weighted average sales price of the shares sold ranging from a low of \$39.03 to a high of \$40.00 per share. The
- (3) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (4) This option vested in forty-eight equal installments beginning on March 16, 2007.
- (5) This option vested in forty-eight equal installments beginning on March 15, 2008.
- (6) This option vested in forty-eight equal installments beginning on March 18, 2011.
- (7) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.